APO-Metformin recall in Canada: May contain NDMA above acceptable limits
In plain language
This recall involves APO-Metformin 500 mg Extended Release Tablets sold in Canada. It's being recalled because affected lots may contain N-nitrosodimethylamine (NDMA) above the acceptable concentration limit. Stop using the product and follow the return steps in the official notice.
What to do
- Stop using the product immediately.
- Check the lot numbers on your medication.
- Return the affected product to your pharmacy.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
APO-Metformin 500 mg Extended Release Tablet
Lot: PK3968, PK3969, PX5336, PY7174, PY7175, RF6463, RF6464, RF6465, RF6466
Why this matters
May contain N-nitrosodimethylamine (NDMA) above acceptable limits
Do I have this product?
This recall only applies to specific products. Follow the steps below to check.
- 1
Check the product name
Make sure your product name matches one of the affected products listed above.
- 2
Check the lot number
Lot numbers identify specific production batches.
Affected lots: PK3968, PK3969, PX5336, PY7174, PY7175, RF6463, RF6464, RF6465, RF6466
If your product matches one or more of the details above, it may be affected by this recall.
If your product does not match these details, it is not affected by this recall.
When in doubt, always check the official notice.
Frequently Asked Questions
Why was this product recalled?
May contain N-nitrosodimethylamine (NDMA) above acceptable limits
What should consumers do?
Stop using the product immediately. Check the lot numbers on your medication. Return the affected product to your pharmacy.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
Yes, there may be a health risk. May contain N-nitrosodimethylamine (NDMA) above acceptable limits
When was this product recalled?
This product was recalled on June 12, 2020.
Is the APO-Metformin brand affected by this recall?
Yes, APO-Metformin products are affected by this recall. This recall involves APO-Metformin 500 mg Extended Release Tablets sold in Canada. It's being recalled because affected lots may contain N-nitrosodimethylamine (NDMA) above the acceptable concentration limit. Stop using the product and follow the return steps in the official notice.